問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

林家齊

List

270Cases

2023-04-01 - 2026-03-31

Phase I

A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AM-928 Infusion in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    AM-928

Participate Sites
3Sites

Not yet recruiting3Sites

2015-06-22 - 2019-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

  • Condition/Disease

    Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma

  • Test Drug

    Ramucirumab (Cyramza)

Participate Sites
8Sites

Terminated7Sites

2015-10-22 - 2019-12-31

Phase I

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    FPA144

Participate Sites
5Sites

Terminated4Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

2013-09-15 - 2016-07-11

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-05-01 - 2020-12-31

Phase I

A phase I/Ib, open-label, multi-center dose escalation study of NIS793 in combination with PDR001 in adult patients with advanced malignancies

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    NIS793, PDR001

Participate Sites
1Sites

Terminated1Sites

2013-01-01 - 2023-08-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-05-01 - 2018-10-05

Phase I

A phase I, multicenter, open-label dose escalation and expansion study of PCA062, administered intravenously in adult patients with pCAD-positive tumors

  • Condition/Disease

    advanced malignancy

  • Test Drug

    PCA062

Participate Sites
1Sites

Terminated1Sites

2015-03-20 - 2019-06-28

Phase I/II

A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or other solid tumors characterized by positive FGFR4 and KLB expression

  • Condition/Disease

    hepatocellular carcinoma or other solid tumors

  • Test Drug

    FGF401

Participate Sites
2Sites

Terminated2Sites

2015-04-19 - 2019-12-31

Others

A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma

  • Condition/Disease

    liposarcoma

  • Test Drug

    HDM201/Ribociclib (LEE011)

Participate Sites
1Sites

Terminated1Sites

2014-08-21 - 2016-12-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 22 23 24 25 26 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB